NCT01459250View on ClinicalTrials.gov

Pharmacokinetics, Safety and Tolerability of AGO178C in Subjects With Renal Deficiencies Compared With Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

August 31, 2011

Conditions
Renal Impairment
Interventions
DRUG

AGO178C

Trial Locations (4)

33136

Novartis Investigative Site, Miami

37920

Novartis Investigative Site, Knoxville

55404

Novartis Investigative Site, Minneapolis

32809-3017

Novartis Investigative Site, Orlando

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY